loading
전일 마감가:
$1.26
열려 있는:
$1.25
하루 거래량:
77,683
Relative Volume:
0.37
시가총액:
$73.01M
수익:
-
순이익/손실:
$-131.52M
주가수익비율:
-0.7247
EPS:
-1.78
순현금흐름:
$-107.56M
1주 성능:
-11.64%
1개월 성능:
+14.16%
6개월 성능:
+82.15%
1년 성능:
-34.02%
1일 변동 폭
Value
$1.20
$1.29
1주일 범위
Value
$1.15
$1.4969
52주 변동 폭
Value
$0.6101
$2.01

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
명칭
Prelude Therapeutics Inc
Name
전화
(302) 467-1280
Name
주소
175 INNOVATION BOULEVARD, WILMINGTON
Name
직원
131
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
PRLD's Discussions on Twitter

PRLD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PRLD
Prelude Therapeutics Inc
1.29 71.32M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.60 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
472.79 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.45 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
801.26 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
331.07 35.16B 4.56B -176.77M 225.30M -1.7177

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-09-19 업그레이드 H.C. Wainwright Neutral → Buy
2024-06-20 다운그레이드 Barclays Equal Weight → Underweight
2024-03-13 개시 JMP Securities Mkt Outperform
2024-02-20 다운그레이드 H.C. Wainwright Buy → Neutral
2023-12-19 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2022-11-21 다운그레이드 BofA Securities Neutral → Underperform
2022-09-09 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-07-29 개시 Jefferies Buy
2022-03-15 다운그레이드 BofA Securities Buy → Neutral
2022-02-28 다운그레이드 Barclays Overweight → Equal Weight
2021-10-08 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-07-27 업그레이드 BofA Securities Neutral → Buy
2021-04-26 개시 H.C. Wainwright Buy
2021-03-09 개시 Barclays Overweight
2020-11-20 다운그레이드 BofA Securities Buy → Neutral
2020-10-20 개시 BofA Securities Buy
2020-10-20 개시 Goldman Neutral
2020-10-20 개시 Morgan Stanley Equal-Weight
모두보기

Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스

pulisher
10:46 AM

Can Prelude Therapeutics Incorporated stock maintain operating marginsEarnings Recap Report & Fast Gaining Stock Reports - newser.com

10:46 AM
pulisher
10:29 AM

Is Prelude Therapeutics Incorporated stock a defensive play in 20252025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com

10:29 AM
pulisher
09:36 AM

How moving averages guide Prelude Therapeutics Incorporated tradingInsider Buying & Weekly Market Pulse Alerts - newser.com

09:36 AM
pulisher
08:48 AM

Is Prelude Therapeutics Incorporated stock supported by innovation pipelineJuly 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com

08:48 AM
pulisher
04:02 AM

Using Bollinger Bands to evaluate Prelude Therapeutics IncorporatedWeekly Trend Report & AI Forecasted Stock Moves - newser.com

04:02 AM
pulisher
01:25 AM

Will Prelude Therapeutics Incorporated stock deliver shareholder value2025 Price Targets & High Return Stock Watch Alerts - newser.com

01:25 AM
pulisher
12:18 PM

Can Prelude Therapeutics Incorporated stock sustain free cash flow growthQuarterly Profit Summary & Safe Capital Growth Stock Tips - newser.com

12:18 PM
pulisher
Oct 09, 2025

Published on: 2025-10-09 05:09:32 - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Can momentum traders help lift Prelude Therapeutics IncorporatedEarnings Summary Report & AI Driven Price Predictions - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Using economic indicators to assess Prelude Therapeutics Incorporated potentialFed Meeting & Safe Capital Allocation Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Published on: 2025-10-09 02:10:25 - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Analyzing Prelude Therapeutics Incorporated with risk reward ratio charts2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

CDK4/6 Inhibitor Market Positioned for Remarkable Growth as Revolutionary Therapies Transform Cancer Treatment Landscape in 2024 - Barchart.com

Oct 06, 2025
pulisher
Oct 05, 2025

Full technical analysis of Prelude Therapeutics Incorporated stock2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Prelude Therapeutics Incorporated rebound enough to break evenEarnings Risk Report & Fast Momentum Entry Tips - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Multi asset correlation models including Prelude Therapeutics IncorporatedInsider Buying & Weekly Watchlist for Consistent Profits - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will earnings trigger a reversal in Prelude Therapeutics IncorporatedPortfolio Return Summary & Verified Swing Trading Watchlists - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

What drives Prelude Therapeutics Incorporated stock priceSector-Based Investing & Double Digit Trading Ideas - earlytimes.in

Oct 02, 2025
pulisher
Sep 28, 2025

Contrasting Cardiol Therapeutics (NASDAQ:CRDL) & Prelude Therapeutics (NASDAQ:PRLD) - Defense World

Sep 28, 2025
pulisher
Sep 27, 2025

Prelude Therapeutics (NASDAQ:PRLD) versus Talphera (NASDAQ:TLPH) Financial Contrast - Defense World

Sep 27, 2025
pulisher
Sep 26, 2025

3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st

Sep 26, 2025
pulisher
Sep 26, 2025

Brokers Set Expectations for PRLD Q3 Earnings - Defense World

Sep 26, 2025
pulisher
Sep 24, 2025

Prelude Therapeutics’ (PRLD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Sep 24, 2025
pulisher
Sep 23, 2025

H.C. Wainwright reiterates Buy rating on Prelude Therapeutics stock with $5 target - Investing.com Canada

Sep 23, 2025
pulisher
Sep 23, 2025

Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

HC Wainwright & Co. Reiterates Buy Rating for PRLD, Price Target at $5.00 | PRLD Stock News - GuruFocus

Sep 23, 2025
pulisher
Sep 22, 2025

New PROTACs revealed in Prelude Therapeutics patent - BioWorld MedTech

Sep 22, 2025
pulisher
Sep 21, 2025

What momentum shifts mean for Prelude Therapeutics IncorporatedInsider Selling & Weekly Return Optimization Plans - newser.com

Sep 21, 2025
pulisher
Sep 21, 2025

Will Prelude Therapeutics Incorporated benefit from macro trendsWeekly Trend Summary & Entry Point Confirmation Signals - newser.com

Sep 21, 2025
pulisher
Sep 20, 2025

Statistical indicators supporting Prelude Therapeutics Incorporated’s strength2025 Investor Takeaways & Consistent Growth Stock Picks - newser.com

Sep 20, 2025
pulisher
Sep 20, 2025

Visual analytics tools that track Prelude Therapeutics Incorporated performance2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com

Sep 20, 2025
pulisher
Sep 20, 2025

New Highs: Is Prelude Therapeutics Incorporated stock a good pick for beginnersJuly 2025 Review & Consistent Profit Focused Trading Strategies - خودرو بانک

Sep 20, 2025
pulisher
Sep 19, 2025

Profit Recap: Will Prelude Therapeutics Incorporated stock go up in YEARWeekly Trade Analysis & Breakout Confirmation Trade Signals - خودرو بانک

Sep 19, 2025

Prelude Therapeutics Inc (PRLD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Prelude Therapeutics Inc 주식 (PRLD) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Vaddi Krishna
CEO
Mar 25 '25
Buy
0.69
675,000
467,438
1,999,296
Vaddi Krishna
CEO
Mar 21 '25
Buy
0.73
15,000
10,959
1,324,296
Vaddi Krishna
CEO
Mar 20 '25
Buy
0.73
5,416
3,950
1,309,296
Vaddi Krishna
CEO
Mar 14 '25
Buy
0.75
29,999
22,631
1,294,774
Vaddi Krishna
CEO
Mar 17 '25
Buy
0.75
9,106
6,829
1,303,880
Vaddi Krishna
CEO
Mar 13 '25
Buy
0.72
50,000
35,820
1,264,775
Vaddi Krishna
CEO
Mar 12 '25
Buy
0.71
47,500
33,744
1,214,775
Vaddi Krishna
CEO
Dec 31 '24
Buy
1.21
5,000
6,044
142,553
Vaddi Krishna
CEO
Dec 30 '24
Buy
1.20
10,000
12,000
137,553
Combs Andrew
Chief Chemistry Officer
Dec 23 '24
Buy
1.37
60,000
82,002
377,623
$84.81
price up icon 1.12%
$22.99
price up icon 7.56%
$32.66
price up icon 2.62%
$102.75
price up icon 0.67%
$164.51
price up icon 1.41%
biotechnology ONC
$331.45
price up icon 3.42%
자본화:     |  볼륨(24시간):